Traws Pharma COO granted 96,899 stock options

Traws Pharma, Inc. reported that its Chief Operating Officer, Nikolay Savchuk, received a grant of stock options as part of his compensation.

Accepted by SEC EDGAR 03/10/2026 - 07:17 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Traws Pharma, Inc. reported that its Chief Operating Officer, Nikolay Savchuk, received a grant of stock options as part of his compensation. He was awarded 96,899 stock options to buy common shares at an exercise price of $1.60 per share, expiring on March 8, 2036. These options were granted under the company’s 2021 Incentive Compensation Plan and will vest 100% on the first anniversary of the grant date, meaning they become fully exercisable after one year. Following this grant, he holds 96,899 options, and there were no open‑market purchases or sales reported in this filing.

Insights

Equity compensation analyst

Routine one-year-vesting option grant to the COO, no share sales.

The Chief Operating Officer, Nikolay Savchuk, received 96,899 stock options with a $1.60 exercise price, expiring in 2036. The grant was made under Traws Pharma’s 2021 Incentive Compensation Plan, highlighting equity-based compensation rather than cash.

The options vest 100% after one year, so he must remain in role until about March 2027 before exercising. No open-market buys or sells were reported, and this appears to be a standard incentive grant, which typically has neutral short-term impact on investors.

Insider Trade Summary

Grant/Award: 96,899 shares

Grant/Award 1 txn

Insider Savchuk Nikolay

Role Chief Operating Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	96,899	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 96,899 contracts (Direct)

Holdings Before and After: Stock Option (right to buy), 0 to 96,899 contracts (Direct)

Footnotes (1)

1. F1. Represents stock options awarded by the Issuer's compensation committee (comprised of independent directors) to the reporting person under the Issuer's 2021 Incentive Compensation Plan, as amended and/or restated through the date hereof. The stock options under this award will vest 100% on the first anniversary of the grant date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Traws Pharma (TRAW) report for Nikolay Savchuk?

Traws Pharma reported that COO Nikolay Savchuk received a grant of 96,899 stock options. These options allow him to buy common shares at $1.60 each as part of equity compensation, rather than reflecting an open-market stock purchase or sale.

What are the key terms of the Traws Pharma (TRAW) stock option grant?

The grant covers 96,899 stock options with a $1.60 exercise price and a March 8, 2036 expiration. All options vest 100% on the first anniversary of the grant date, giving the COO a long-dated incentive to stay and potentially benefit from future share price appreciation.

Did the Traws Pharma (TRAW) COO buy or sell common stock in this Form 4?

No common stock was bought or sold on the market in this Form 4. The filing reports only a stock option grant to the COO, with 96,899 options awarded as compensation, not a cash transaction involving existing shares in open-market trading.

How many Traws Pharma (TRAW) options does the COO hold after this transaction?

After the reported transaction, COO Nikolay Savchuk holds 96,899 stock options. This entire position comes from the new grant described in the filing, giving him potential future rights to purchase common shares if the options vest and he chooses to exercise.

When do the new Traws Pharma (TRAW) stock options vest for the COO?

The options vest 100% on the first anniversary of the grant date. This means none are initially exercisable, but all 96,899 options become exercisable together after one year, aligning the COO’s potential benefit with at least a year of continued service.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Savchuk Nikolay

(Last) (First) (Middle)

C/O TRAWS PHARMA, INC.

12 PENNS TRAIL

(Street)

NEWTOWN PA 18940

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Traws Pharma, Inc. [ TRAW ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/08/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$1.6	03/08/2026		A		96,899		03/08/2027(1)	03/08/2036	Common Stock	96,899	$0	96,899	D

Explanation of Responses:

1. Represents stock options awarded by the Issuer's compensation committee (comprised of independent directors) to the reporting person under the Issuer's 2021 Incentive Compensation Plan, as amended and/or restated through the date hereof. The stock options under this award will vest 100% on the first anniversary of the grant date.

	/s/ Nikolay Savchuk	03/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.